We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving breast cancer patients: a single-centre retrospective observational study.
- Authors
Jagiełło-Gruszfeld, Agnieszka; Niwińska, Anna; Michalski, Wojciech; Pogoda, Katarzyna; Dubiański, Roman; Kunkiel, Michał; Lemańska, Izabela; Sienkiewicz, Renata; Górniak, Anna; Kosakowska, Ewa; Nowecki, Zbigniew
- Abstract
A retrospective observational study of the outcomes of darbepoetin alfa treatment for chemotherapy-induced anaemia in breast cancer patients was conducted. A group of 152 patients treated during 13 months in one oncology centre was assessed. Ninety-eight patients (64.5%) received perioperative chemotherapy, and 54 patients (35.5%) received palliative chemotherapy. The results of treatment with darbepoetin alfa were analysed by age (< 65 vs. ≥ 65 years), the aim of chemotherapy (perioperative vs. palliative), and body mass index (< 25 vs. 25-29 vs. 30 and more). The effectiveness of the therapy was estimated at 80.9% (95% CI: 74.7-87.2%). Significantly higher effectiveness of ESA was found in patients treated perioperatively compared to patients treated for metastatic breast cancer (85.7% vs. 72.2%, p = 0.043). There were no differences in the effectiveness of ESA depending on age and BMI. No serious ESA-related adverse events were observed.
- Subjects
DARBEPOETIN alfa; CANCER chemotherapy; BREAST cancer patients; BODY mass index; ERYTHROPOIETIN
- Publication
Oncology in Clinical Practice (2450-1654), 2021, Vol 17, Issue 6, p237
- ISSN
2450-1654
- Publication type
Article
- DOI
10.5603/OCP.2020.0048